New lung cancer drug shows dramatic results for shrinking tumours

Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Centre. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumours in some patients during Phase I and II clinical trials...

Read the whole article on

More from